Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy

Hye Jin Kang, Han Hee Lee, Seung-Eun Jung, Kyung-Sin Park, Joo-Hyun O, Young-Woo Jeon, Byung-Ock Choi, Sook-Goo Cho.

1 Department of Radiation Oncology, Catholic University Lymphoma Group, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 2 Department of Gastroenterology, Catholic University Lymphoma Group, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 3 Department of Radiology, Catholic University Lymphoma Group, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 4 Department of Pathology, Catholic University Lymphoma Group, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 5 Department of Nuclear Medicine, Catholic University Lymphoma Group, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 6 Department of Hematology, Catholic University Lymphoma Group, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 7 Department of Hematology, Catholic University Lymphoma Group, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

* choibo67@catholic.ac.kr (BOC); chosg@catholic.ac.kr (SGC)

Abstract

Purpose

The optimal treatment for primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is still unknown. We evaluated unfavorable prognostic factors and pattern of failure in PG-DLBCL to determine the optimal treatment strategy.

Methods

Between April 2001 and November 2018, 120 patients with complete remission following rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy were retrospectively reviewed. According to the Lugano staging system, 80 patients (66.7%) had localized disease and 40 patients (33.3%) had advanced disease. A total of 93 (77.5%) patients had single gastric lesion and 27 (22.5%) patients had multiple gastric lesions. Ninety patients (75%) were treated with R-CHOP chemotherapy alone and 30 patients (25%) received R-CHOP chemotherapy with additional local treatment for gastric lesions.

Results

The 5-year locoregional failure-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) rates in patients treated with R-CHOP chemotherapy with local
treatment were 100%, 100%, and 100%, respectively, whereas the LRFS, PFS, and OS rates in patients treated with R-CHOP chemotherapy alone were 86.3%, 78.2%, and 87.4%, respectively (p = 0.031, p = 0.095, and p = 0.025, respectively). During the follow-up period, 17 patients (14.2%) had disease recurrence. Only 3 of the 17 patients had relapse in a completely new site without relapse in the initial involved site. All, except 2, cases of local recurrence included gastric failure. In the multivariate analysis, performance status and number of gastric lesions were independent prognostic factors for treatment outcome.

Conclusions
Patients with complete remission following R-CHOP chemotherapy showed a good prognosis. The main pattern of failure in patients with PG-DLBCL was local recurrence, especially in the stomach. Patients who received local treatment for gastric lesions showed improved gastric control. Therefore, in patients with unfavorable prognostic factors, we recommend R-CHOP chemotherapy with additional local treatment for gastric lesions.

Introduction
The stomach is the most commonly involved extranodal site in non-Hodgkin lymphoma, and diffuse large B-cell lymphoma (DLBCL) is the most common histologic type (40%–70%) of gastric lymphoma [1, 2]. The common symptoms of gastric lymphoma at presentation are usually nonspecific symptoms similar to those of gastritis, including epigastric pain, nausea, vomiting, abdominal fullness, and indigestion [3].

Treatments for primary gastric DLBCL (PG-DLBCL) are varied and can include surgical resection, systemic chemotherapy, and radiotherapy (RT) [4]. The optimal treatment for PG-DLBCL still remains unclear. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been commonly used as a treatment strategy for DLBCL. Numerous clinical studies have demonstrated that adding rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy improves progression free-survival (PFS) and overall survival (OS). Therefore, this approach has become the gold standard treatment for general DLBCL [5–8]. The principles of treatment of PG-DLBCL follow those of general DLBCL [9]. PG-DLBCL has a predominantly localized stage and shows a good prognosis with appropriate treatment [10]. Rituximab plus CHOP (R-CHOP) chemotherapy results in a 5-year OS of 90% in patients with PG-DLBCL [4, 11].

However, some patients still have an unfavorable prognosis. Prognostic factors associated with treatment outcome are still controversial. Therefore, it is necessary to predict the subgroups with a high risk of relapse and provide additional treatment for patients receiving R-CHOP chemotherapy. In an attempt to clarify the issue and determine the optimal treatment strategy, we conducted a retrospective evaluation of the unfavorable prognostic factors and pattern of the initial disease failure in PG-DLBCL.

Materials and methods
Patients and ethics
After obtaining approval from the institutional review board (Seoul St. Mary’s Hospital, The Catholic University of Korea; reference number, KC19RESI0346), we retrospectively reviewed patient data. In this study all patients’ records were analyzed in a fully anonymized and de-
identified manner and no researcher had access to patients’ personal information, thus written informed consent was waived. Between April 2001 and November 2018, a total of 152 patients had histologically confirmed DLBCL and were diagnosed with primary gastric lymphoma according to the criteria defined by D’Amore et al. [12]. In the case of DLBCL with systemic involvement, PG-DLBCL was considered when there was a main bulky mass in the stomach. Patients with refractory disease who did not achieve complete remission (CR) following R-CHOP chemotherapy, were not treated with the R-CHOP regimen, and had incomplete treatment records were excluded. A total of 120 patients with PG-DLBCL were included in the study. All patients underwent staging investigations, including physical examination; laboratory data analysis; contrast-enhanced computed tomography (CT) of the neck, chest, and abdomen; 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT; bone marrow aspiration and biopsy; and esophagogastroduodenoscopy (EGD) with biopsy. According to the Lugano staging system for gastrointestinal lymphoma, stages I and II were classified as localized disease, whereas stages II, IIE, and IV were classified as advanced disease [13]. Multiple gastric lesions were defined as the presence of ≥2 separated lesions in the stomach.

Treatments

All patients received 6–8 cycles of R-CHOP chemotherapy. The total number of R-CHOP cycles was determined by the interim treatment response after 3 cycles of R-CHOP chemotherapy. Patients who achieved CR in the interim response evaluation received 6 cycles of R-CHOP chemotherapy, and those who achieved partial response or in whom the disease was stable received up to 8 cycles.

Furthermore, 90 patients (75%) were treated with R-CHOP chemotherapy alone, while the remaining 30 patients (25%) received R-CHOP chemotherapy with local treatment, such as surgical resection and RT for gastric lesions. Twelve patients (10%) underwent total or subtotal gastrectomy before or during R-CHOP chemotherapy for alleviation of symptoms, e.g., perforation, uncontrolled bleeding, and obstruction. All the 12 patients with surgical resection received 6 cycles of R-CHOP chemotherapy and did not receive RT to prevent duplication of local treatment. Another group of 18 patients (15%) received consolidative RT on the stomach after achieving CR to R-CHOP chemotherapy as part of upfront treatment. RT was started within 8 weeks after completion of R-CHOP chemotherapy. The median RT dose was 30.6 Gy (range, 30.6–42 Gy) at 1.8–2 Gy per fraction. The clinical target volume (CTV) is the whole stomach with or without involved perigastric lymph node. The planning target volume was created by adding 1.5–2 cm margin to CTV. With the development of RT technique in our institution, patients were treated with conventional external beam, 3-dimensional conformal, or intensity-modulated RT. The use of consolidative RT was independently decided by patients’ attending physicians and retrospectively collected by researchers.

Response to treatment, follow-up and statistical analysis

Tumor response was evaluated by EGD, contrast-enhanced CT, and PET/CT every 3 cycles and 1 month after completion of R-CHOP chemotherapy. CR was defined as complete resolution of all lesions on CT or FDG avidity score of 1–3 on PET/CT according to the Deauville criteria (5-point scale) [14]. All patients underwent endoscopy with biopsies of the stomach to confirm CR. Patients were followed at 1 month after completion of treatment, every 3 months for the first 2 years, and every 6 months thereafter. Physical examination, laboratory data analysis, and CT were performed at each visit. EGD was performed annually.

The primary study endpoint was locoregional failure-free survival (LRFS). The secondary endpoints were PFS and OS. LRFS was defined as the duration from the date of diagnosis to
the date of disease relapse in the initial involved site, death from any cause, or last follow-up visit if a patient was free of disease. PFS was defined as the duration from the date of diagnosis to the date of disease relapse in any site, death from any cause, or last follow-up visit if a patient was free of disease. OS was defined as the time from diagnosis to death from any cause or last follow-up visit. The survival curves of LRFS, PFS, and OS were calculated using the Kaplan–Meier method. Univariate analyses were performed using log-rank test to assess the prognostic factor related to survival. Potential prognostic factors with \( p < 0.1 \) in the univariate analyses were included in the multivariate analyses. Multivariate analyses were performed using the Cox proportional-hazards model. All test results were two-sided. A \( P \)-value of \(< 0.05 \) was considered statistically significant. All statistical analyses were performed using the R (version 3.4.4).

**Results**

**Patient characteristics and treatment outcome**

The patient characteristics are summarized in Table 1. The median age was 59 years (range, 21–87 years). Women slightly outnumbered men (53.3\% vs. 46.7\%). The Lugano stage at diagnosis was as follows: 80 patients (66.7\%) had localized disease, and 40 patients (33.3\%) had advanced disease. A total of 93 (77.5\%) patients had single gastric lesion, and 27 (22.5\%) patients had multiple gastric lesions. Patients treated with R-CHOP chemotherapy with local treatment showed statistically significant higher percentages of younger age, GCB type, bulky gastric lesion, and lower IPI score than those treated with R-CHOP chemotherapy alone.

The median follow-up duration was 49 months (range, 5–197 months). The estimated actuarial 5-year LRFS, PFS, and OS rates in all patients were 85.6\% (95\% confidence interval [CI], 78.7–93.7), 83.4\% (95\% CI, 76.1–91.5), and 90.3\% (95\% CI, 84.7–96.2), respectively. The 5-year LRFS, PFS, and OS rates in patients with localized disease were 91.5\%, 88.3\%, and 94.4\%, respectively, whereas the LRFS, PFS, and OS rates in patients with advanced disease were 74.2\%, 74.2\%, and 81.3\%, respectively \( (p = 0.005, p = 0.009, \text{and } p = 0.195, \text{respectively; Fig 1}) \).

We also evaluated treatment outcomes according to treatment modalities and found that survival rates of patients who had received combined R-CHOP chemotherapy and local treatments were higher than those who received R-CHOP chemotherapy alone. The 5-year LRFS, PFS, and OS rates in patients treated with R-CHOP chemotherapy with local treatment were 100\%, 100\%, and 100\%, respectively, whereas the LRFS, PFS, and OS rates in patients treated with R-CHOP chemotherapy alone were 86.3\%, 78.2\%, and 87.4\%, respectively \( (p = 0.031, p = 0.095, \text{and } p = 0.025, \text{respectively; Fig 2}) \).

**Prognostic factors associated with treatment outcome**

In the univariate analysis, a lower LRFS rate was significantly strongly associated with old age \( (p = 0.042) \), advanced Lugano stage \( (p = 0.005) \), poor performance status \( (p = 0.040) \), non-germinal center B cell-like (GCB) type \( (p = 0.041) \), multiple gastric lesions \( (p < 0.001) \), higher international prognostic index (IPI) score \( (p = 0.018) \), and R-CHOP alone without local treatment \( (p = 0.031) \). The lower PFS rate was associated with old age \( (p = 0.020) \), advanced Lugano stage \( (p = 0.009) \), poor performance status \( (p = 0.044) \), multiple gastric lesions \( (p = 0.006) \), and higher IPI score \( (p = 0.023) \). The treatment modality tended to be associated with the PFS \( (p = 0.095) \). The lower OS rate was associated with non-GCB type \( (p = 0.020) \), multiple gastric lesions \( (p < 0.001) \), and R-CHOP chemotherapy alone without local treatment \( (p = 0.025) \). Detailed results of the univariate analysis on survival are shown in Table 2. In the multivariate analysis, the Eastern Cooperative Oncology Group (ECOG) performance status (hazard ratio
The number of gastric lesions (HR, 6.59; \( p < 0.001 \)) was an independent prognostic factor for LRFS. The number of gastric lesions was the only associated factor for PFS and OS (HR, 4.04, \( p = 0.005 \) for PFS; HR, 7.63, \( p = 0.001 \) for OS). The 5-year LRFS, PFS, and OS rates in patients with single gastric lesion were 91.8%, 88.9%, and 95.1%, respectively.

### Table 1. Patient characteristics.

| Characteristics     | Total (n = 120) | Without local Tx. (n = 90) | With local Tx. (n = 30) | \( p \)-value |
|---------------------|----------------|---------------------------|-------------------------|---------------|
| Age (years)         |                |                           |                         | 0.011         |
| <60                 | 62 (51.7)      | 40 (44.4)                 | 22 (73.3)               |               |
| \( \geq 60 \)       | 58 (48.3)      | 50 (55.6)                 | 8 (26.7)                |               |
| Sex                 |                |                           |                         | 1.000         |
| Male                | 56 (46.7)      | 42 (46.7)                 | 14 (46.7)               |               |
| Female              | 64 (53.3)      | 48 (53.3)                 | 16 (53.3)               |               |
| Lugano stage        |                |                           |                         | 0.264         |
| I/II\(_{1}\)        | 80 (66.7)      | 57 (63.3)                 | 23 (76.7)               |               |
| II\(_{2} /I_{II}/IV | 40 (33.3)      | 33 (36.7)                 | 7 (23.3)                |               |
| ECOG                |                |                           |                         | 0.057         |
| 0                   | 54 (45.0)      | 35 (38.9)                 | 19 (63.3)               |               |
| 1                   | 49 (40.8)      | 40 (44.4)                 | 9 (30.0)                |               |
| \( \geq 2 \)        | 17 (14.2)      | 15 (16.7)                 | 2 (6.7)                 |               |
| B symptom           |                |                           |                         | 0.777         |
| Present             | 20 (16.7)      | 16 (17.8)                 | 4 (13.3)                |               |
| Absent              | 100 (83.3)     | 74 (82.2)                 | 26 (86.7)               |               |
| Lactate dehydrogenase |             |                           |                         | 0.915         |
| Normal              | 71 (59.2)      | 54 (60.0)                 | 17 (56.7)               |               |
| Elevated            | 49 (40.8)      | 36 (40.0)                 | 13 (43.3)               |               |
| Pathologic type     |                |                           |                         | 0.018         |
| GCB type            | 48 (40.0)      | 33 (36.7)                 | 15 (50.0)               |               |
| Non-GCB type        | 50 (41.7)      | 45 (50.0)                 | 5 (16.6)                |               |
| Missing             | 22 (18.3)      | 12 (13.3)                 | 10 (33.4)               |               |
| EBV                 |                |                           |                         | 0.152         |
| Positive            | 21 (17.5)      | 61 (67.8)                 | 23 (76.7)               |               |
| Negative            | 84 (70.0)      | 19 (21.1)                 | 2 (6.7)                 |               |
| Missing             | 15 (12.5)      | 10 (11.1)                 | 5 (16.6)                |               |
| Extranodal involvement |            |                           |                         | 0.039         |
| 1 (stomach only)    | 93 (77.5)      | 66 (73.3)                 | 27 (90.0)               |               |
| \( \geq 2 \)        | 27 (22.5)      | 24 (16.7)                 | 3 (10.0)                |               |
| Bulky disease status|                |                           |                         | 0.900         |
| Non bulky (<5 cm)   | 45 (37.5)      | 39 (43.3)                 | 6 (20.0)                |               |
| Bulky (>5 cm)       | 75 (62.5)      | 51 (56.7)                 | 24 (80.0)               |               |
| No. of gastric lesion |             |                           |                         | 0.900         |
| Single              | 93 (77.5)      | 69 (76.7)                 | 24 (80.0)               |               |
| Multiple            | 27 (22.5)      | 21 (23.3)                 | 6 (20.0)                |               |
| IPI score           |                |                           |                         | 0.041         |
| <3                  | 89 (74.2)      | 62 (68.9)                 | 27 (90.0)               |               |
| \( \geq 3 \)        | 31 (25.8)      | 28 (31.1)                 | 3 (10.0)                |               |

Abbreviations: ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B cell-like; EBV, Epstein–Barr virus; IPI, international prognostic index

https://doi.org/10.1371/journal.pone.0238807.t001
whereas the LRFS, PFS, and OS rates in patients with multiple gastric lesions were 64.8%, 64.8%, and 73.2%, respectively (p < 0.001, p = 0.006, and p < 0.001, respectively; Fig 3).

Patterns of failure and salvage treatment

During the follow-up period, 17 patients (14.2%) had disease relapse. The median time interval to relapse was 13 months (range, 4–80 months). A detailed pattern of the initial failure for individual cases is shown in Table 3. Seven patients had localized disease and 10 patients had advanced disease. Only 3 of the 17 patients had relapse in a completely new site without locoregional failure in the initial involved site. The sites of relapse were the lymph node (n = 2) and brain (n = 1). Furthermore, 14 of the 17 patients had the first relapse in the initial involved site, except in 2 patients; the site of relapse was the stomach with or without regional lymphatics. All disease relapses in patients with multiple gastric lesions occurred in the stomach.

Furthermore, 15 of the 17 patients with relapse were treated with either salvage RT or second-line chemotherapy (i.e., dexamethasone, cytarabine, and cisplatin and ifosfamide, cisplatin, and etoposide). Only 5 patients achieved CR following salvage treatment, while the others had disease progression despite the intensive salvage treatment.

Discussion

According to the treatment of general DLBCL, R-CHOP chemotherapy is the backbone treatment for PG-DLBCL. We performed R-CHOP chemotherapy as the first-line treatment in all patients with PG-DLBCL in the study. Although approximately one-third of the patients had stages II_2 to IV, which was a relatively high proportion of patients with advanced disease, consistent with those in previous reports published in the rituximab era, the 5-year OS rate was

Fig 1. Kaplan–Meier curves of (A) locoregional failure-free survival (LRFS, p = 0.005), (B) progression-free survival (PFS, p = 0.009), and (C) overall survival (OS, p = 0.195) by Lugano stage.

https://doi.org/10.1371/journal.pone.0238807.g001

Fig 2. Kaplan–Meier curves of (A) locoregional failure-free survival (LRFS, p = 0.031), (B) progression-free survival (PFS, p = 0.095), and (C) overall survival (OS, p = 0.025) by treatment modality.

https://doi.org/10.1371/journal.pone.0238807.g002
We evaluated the prognostic factors and pattern of failure in patients with stages I to IV PG-DLBCL achieving CR following R-CHOP chemotherapy.

Age, Lugano stage, pathologic subtype, IPI score—well-known prognostic factors identified in several previous studies [15–17]—had statistically significant results in the univariate analysis but lost significance in the multivariate analysis. Additional local treatment to the stomach also showed a significant difference in treatment outcomes only in the univariate analysis.

Table 2. Univariate analysis for LRFS, PFS, and OS.

| Variable                  | 5-year LRFS (%) | 95% CI    | p-value | 5-year PFS (%) | 95% CI    | p-value | 5-year OS (%) | 95% CI    | p-value |
|---------------------------|-----------------|-----------|---------|----------------|-----------|---------|----------------|-----------|---------|
| Age (years)               |                 |           |         |                |           |         |                |           |         |
| <60                       | 91.7            | 84.0–100  | 0.042   | 89.3           | 80.7–98.9 | 0.020   | 92.0           | 84.6–99.9 | 0.203   |
| ≥60                       | 79.0            | 67.8–92.0 |          | 77.3           | 65.9–90.5 |          | 85.5           | 76.1–96.1 |         |
| Sex                       |                 |           |         |                |           |         |                |           |         |
| Male                      | 86.8            | 76.8–98.0 | 0.810   | 86.8           | 76.8–98.0 | 0.636   | 87.6           | 78.8–97.5 | 0.108   |
| Female                    | 84.8            | 75.6–95.2 |          | 80.8           | 70.7–92.5 |          | 92.7           | 86.0–99.9 |         |
| Lugano stage              |                 |           |         |                |           |         |                |           |         |
| I/Ii/IiI/IV               |                 |           |         |                |           |         |                |           |         |
| I/II                      | 91.5            | 84.4–99.2 | 0.005   | 88.3           | 80.3–97.1 | 0.009   | 94.4           | 89.1–99.9 | 0.195   |
| II/Ii/III/IV              | 74.2            | 60.9–90.4 |          | 74.2           | 60.9–90.4 |          | 81.3           | 68.7–96.2 |         |
| ECOG                      |                 |           |         |                |           |         |                |           |         |
| 0                         | 95.3            | 89.2–100  | 0.040   | 92.4           | 84.3–100  | 0.044   | 97.7           | 93.4–100  | 0.069   |
| 1                         | 81.0            | 69.6–94.2 |          | 65.8           | 44.5–97.4 |          | 86.1           | 76.3–97.2 |         |
| ≥2                        | 70.2            | 48.8–100  |          | 70.2           | 48.8–100  |          | 78.6           | 59.8–100  |         |
| B symptom                 |                 |           |         |                |           |         |                |           |         |
| Present                   | 85.8            | 78.1–94.3 | 0.650   | 83.2           | 75.0–92.4 | 0.506   | 91.7           | 86.0–97.8 | 0.512   |
| Absent                    | 85.3            | 68.8–100  |          | 84.0           | 68.8–100  |          | 82.6           | 66.6–100  |         |
| Lactate dehydrogenase     |                 |           |         |                |           |         |                |           |         |
| Normal                    | 88.6            | 80.8–97.1 | 0.352   | 84.9           | 76.1–94.8 | 0.838   | 90.7           | 83.9–98.1 | 0.822   |
| Elevated                  | 81.2            | 69.2–95.3 |          | 81.2           | 69.2–95.3 |          | 89.7           | 80.6–99.8 |         |
| Pathologic type           |                 |           |         |                |           |         |                |           |         |
| GCB type                  | 90.8            | 81.4–100  | 0.041   | 87.7           | 76.1–99.8 | 0.087   | 97.4           | 92.6–100  | 0.020   |
| Non-GCB type              | 75.4            | 62.2–91.3 |          | 73.5           | 60.2–89.6 |          | 82.9           | 72.1–95.4 |         |
| Extranodal involvement    |                 |           |         |                |           |         |                |           |         |
| 1 (stomach only)          | 87.9            | 80.5–95.9 | 0.129   | 85.2           | 77.2–94.0 | 0.107   | 90.3           | 84.1–96.9 | 0.762   |
| ≥2                        | 77.6            | 61.8–97.4 |          | 77.6           | 61.8–97.4 |          | 90.4           | 78.6–100  |         |
| Bulky disease status      |                 |           |         |                |           |         |                |           |         |
| Non bulky (<5 cm)         | 88.8            | 78.9–99.9 | 0.389   | 85.3           | 73.9–98.3 | 0.410   | 90.6           | 82.2–99.8 | 0.557   |
| Bulky (≥5 cm)             | 83.8            | 74.8–93.9 |          | 82.4           | 73.3–92.8 |          | 90.1           | 82.8–98.0 |         |
| No. of gastric lesion      |                 |           |         |                |           |         |                |           |         |
| Single                    | 91.8            | 85.7–98.4 | <0.001  | 88.9           | 81.9–96.6 | 0.006   | 95.1           | 90.6–99.9 | <0.001  |
| Multiple                  | 64.8            | 47.1–89.4 |          | 64.8           | 47.1–89.4 |          | 73.2           | 56.8–94.5 |         |
| IPI score                 |                 |           |         |                |           |         |                |           |         |
| <3                        | 89.4            | 82.0–97.5 | 0.018   | 86.5           | 78.3–95.5 | 0.023   | 93.5           | 88.2–99.2 | 0.521   |
| ≥3                        | 74.1            | 59.1–92.8 |          | 74.1           | 59.1–92.8 |          | 79.7           | 65.3–97.3 |         |
| Treatment modality        |                 |           |         |                |           |         |                |           |         |
| Without local Tx.         | 83.5            | 75.7–92.1 | 0.031   | 78.2           | 69.0–88.8 | 0.095   | 87.4           | 80.3–95.0 | 0.025   |
| With local Tx.            | 100             |            |           |                |           |         |                |           |         |

Abbreviations: LRFS, locoregional failure-free survival; PFS, progression-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B cell-like; IPI, international prognostic index; CI, confidence interval

https://doi.org/10.1371/journal.pone.0238807.t002

90.3% [4, 11]. We evaluated the prognostic factors and pattern of failure in patients with stages I to IV PG-DLBCL achieving CR following R-CHOP chemotherapy.

Age, Lugano stage, pathologic subtype, IPI score—well-known prognostic factors identified in several previous studies [15–17]—had statistically significant results in the univariate analysis but lost significance in the multivariate analysis. Additional local treatment to the stomach also showed a significant difference in treatment outcomes only in the univariate analysis.
Rather than showing a truly low significance, this finding might reflect a lack of statistical power due to the small number of relapse cases. The multivariate analysis identified that the ECOG performance status and number of gastric lesions were the only independent prognostic factors. Poor ECOG performance status predicted significantly worse LRFS (HR, 2.15; \( p = 0.038 \)) and marginally worse PFS (HR, 1.72; \( p = 0.098 \)) and OS (HR, 1.99; \( p = 0.064 \)). It was considered to provide insufficient dose of R-CHOP chemotherapy to control patients with poor performance status. Only half of patients with grade 2 ECOG performance status received the full dose of R-CHOP chemotherapy, while the other half received attenuated dose from 75% to 50% of the full dose. Similar to our results, Lin et al. also demonstrated that a better ECOG performance status was related to better PFS and OS by enabling more intensive chemotherapy regimen and adequate cycle of chemotherapy to be performed in patients with DLBCL [18]. Furthermore, in line with previously published results [19, 20], multiple gastric

![Fig 3. Kaplan–Meier curves of (A) locoregional failure-free survival (LRFS, \( p < 0.001 \)), (B) progression-free survival (PFS, \( p = 0.006 \)), and (C) overall survival (OS, \( p < 0.001 \)) by number of gastric lesions.](https://doi.org/10.1371/journal.pone.0238807.g003)

### Table 3. Pattern of failure for individual case.

| No. | Age/sex | Stage | ECOG | IPI | Pathologic type | Gastric lesion | Extranodal involvement | Therapy | Time to failure (months) | Recurrence site |
|-----|---------|-------|------|-----|-----------------|----------------|------------------------|---------|------------------------|----------------|
| 1   | 66/F    | I     | 1    | 1   | GCB            | Single         |                        | R-CHOP 50% | 24                      | Stomach*
| 2   | 83/F    | I     | 1    | 1   | GCB            | Single         |                        | R-CHOP 50% | 31                      | Stomach*
| 3   | 53/F    | I     | 0    | 0   | GCB            | Single         |                        | R-CHOP 100% | 42                      | Cervical LN*
| 4   | 63/F    | I     | 1    | 1   | Non-GCB        | Single         |                        | R-CHOP 100% | 9                       | Brain*
| 5   | 45/M    | II    | 1    | 2   | Non-GCB        | Multiple       |                        | R-CHOP 100% | 53                      | Stomach*
| 6   | 64/F    | II    | 1    | 1   | Missing        | Multiple       |                        | R-CHOP 100% | 4                       | Stomach*
| 7   | 37/M    | II    | 1    | 1   | Non-GCB        | Multiple       |                        | R-CHOP 100% | 4                       | Stomach*
| 8   | 65/F    | IV    | 1    | 3   | Non-GCB        | Multiple       |                        | R-CHOP 100% | 13                      | Stomach, cervical LN*
| 9   | 63/M    | IV    | 1    | 2   | Non-GCB        | Multiple       |                        | R-CHOP 100% | 10                      | Stomach*
| 10  | 72/M    | IV    | 1    | 3   | Non-GCB        | Single         |                        | R-CHOP 100% | 6                       | Stomach, pelvic LN*
| 11  | 72/M    | IV    | 1    | 4   | Non-GCB        | Single         | Colon                  | R-CHOP 100% | 8                       | Stomach*
| 12  | 62/F    | IV    | 0    | 4   | Non-GCB        | Multiple       | Liver, GB              | R-CHOP 75% | 16                      | Stomach*
| 13  | 54/F    | IV    | 0    | 2   | GCB            | Single         | Spleen, lung           | R-CHOP 100% | 23                      | Spleen*
| 14  | 64/F    | IV    | 2    | 4   | Non-GCB        | Multiple       | Colon                  | R-CHOP 50% | 5                       | Stomach*
| 15  | 69/F    | IV    | 2    | 3   | Non-GCB        | Single         |                        | R-CHOP 50% | 14                      | Left. iliac LN*
| 16  | 52/M    | IV    | 2    | 4   | Non-GCB        | Multiple       | Spleen, mesentery      | R-CHOP 100% | 4                       | Stomach, mesentery*
| 17  | 66/M    | IV    | 1    | 3   | GCB            | Single         | BM                     | R-CHOP 100% | 80                      | Cervical LN*

Abbreviations: ECOG, Eastern Cooperative Oncology Group; IPI, international prognostic index; GCB, germinal center B cell-like; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone

*Isolated relapse in a completely new site

[https://doi.org/10.1371/journal.pone.0238807.t003](https://doi.org/10.1371/journal.pone.0238807.t003)
lesions were also identified for LRFS (HR, 6.59; \( p < 0.001 \)), PFS (HR, 4.04; \( p = 0.005 \)), and OS (HR, 7.63; \( p = 0.001 \)). For instance, Liu et al. reported that multiple gastric lesions were an independent adverse prognostic factor of OS (\( p = 0.011 \)) [19]. Furthermore, Ishikawa et al. proposed a prognostic model of primary gastric DLBCL using the adverse prognostic factor, including multiple gastric lesions [20].

We found notable results in the site of relapse regardless of the pathologic subtype. About 80% of patients had failure at the initial involved sites even after achieving CR, 90% of them had gastric failure. Moreover, all disease relapses in patients with multiple gastric lesions occurred in the stomach (Table 3). Our findings are consistent with previously published data where the most common pattern of initial failure was local relapse following systemic therapy alone, compromising 44%–63% of all of disease failure cases [21–24].

A quarter of patients in this study underwent additional local treatment for gastric lesions. Patients who received local stomach treatment showed significantly improved gastric control compared with those who received R-CHOP chemotherapy alone at the 5-year follow-up (100% vs. 88.2%, \( p = 0.044 \)). The benefits of local treatment on local control were also reported in a study by Li’s et al [9]. The authors achieved 100% local control in patients treated with consolidative RT at the 10-year follow-up (\( p = 0.028 \)).

The pattern of failure and treatment outcome according to treatment modalities suggest a potential role for local treatment of the stomach. In the present study, surgical resection or consolidative RT was used as a local treatment for the stomach. Until the early 2000s, the surgical approach to gastric lesion was the standard treatment procedure for curative aim. However, postoperative complications, such as dumping syndrome, malabsorption syndrome, and impairment of quality of life, were constantly reported [25]. Moreover, systemic therapy with consolidative RT showed equivalent treatment outcomes but lower treatment-related morbidity compared to those of the surgical approach [10, 26]. No major acute and late RT-related toxicities, including gastric complication, liver dysfunction, and renal insufficiency, were found when consolidative dose was delivered to the stomach in a study conducted by Liu X et al. [15]. Surgical resection should be limited in treating complications and has been replaced by the conservative treatment approach. In our data, gastrectomy was performed in 12 patients only for palliative purposes before or during R-CHOP chemotherapy e.g., perforation, uncontrolled bleeding, and obstruction. Moreover, another 18 patients received consolidative RT on the stomach when they achieved CR after R-CHOP chemotherapy. The use of consolidative RT was independently decided by patients’ attending physicians. Although it was difficult to obtain detailed records of RT-related toxicity in our retrospective data, all patients completed the full course of RT, even those of advanced age or with poor ECOG performance status without interruptions due to RT-induced toxicities.

Additionally, only 5 of the 15 patients (33.3%) who received salvage treatment after relapse achieved CR, and the remaining 10 patients were unable to prevent disease progression despite the use of salvage treatment. Therefore, a more certain type of therapeutic strategy is required from the initial treatment of patients at a high risk of relapse.

Therefore, most patients with PG-DLBCL showed favorable treatment outcomes, and R-CHOP chemotherapy alone was sufficient. However, a more intensive treatment was required in subgroups with a high risk of relapse. Therefore, in patients with unfavorable prognostic factors, such as multiple gastric lesions, dose attenuation of R-CHOP chemotherapy for poor performance status, or old age, we recommend R-CHOP chemotherapy with additional local treatment to the stomach, such as consolidative RT even after achieving CR. Further prospective studies with a large sample size are needed to help illuminate the role of local treatment to the stomach in patients with PG-DLBCL.
Author Contributions

Conceptualization: Byung-Ock Choi.

Data curation: Hye Jin Kang, Young-Woo Jeon, Byung-Ock Choi.

Formal analysis: Hye Jin Kang.

Investigation: Han Hee Lee, Seung-Eun Jung, Kyung-Sin Park, Joo-Hyun O, Young-Woo Jeon.

Project administration: Young-Woo Jeon.

Supervision: Seok-Goo Cho.

Writing – original draft: Hye Jin Kang.

Writing – review & editing: Hye Jin Kang.

References

1. Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World journal of gastroenterology. 2011; 17(6):697–707. Epub 2011/03/11. https://doi.org/10.3748/wjg.v17.i6.697 PMID: 21390139; PubMed Central PMCID: PMC3042647.

2. Newton R, Ferlay J, Beral V, Devesa SS. The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites. International journal of cancer. 1997; 72(6):923–30. Epub 1997/11/05. https://doi.org/10.1002/(sici)1097-0215(19970917)72:6<923::aid-ijc1>3.0.co;2-i PMID: 9378552.

3. Juarez-Salcedo LM, Sokol L, Chavez JC, Dalia S. Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment. Cancer control: journal of the Moffitt Cancer Center. 2018; 25(1):1073274818778256. Epub 2018/05/22. https://doi.org/10.1177/1073274818778256 PMID: 29779412; PubMed Central PMCID: PMC6028179.

4. Ferreri AJ, Montalban C. Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol. 2007; 63(1):65–71. Epub 2007/03/07. https://doi.org/10.1016/j.critrevonc.2007.01.003 PMID: 17339119.

5. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England journal of medicine. 2002; 346(4):235–42. Epub 2002/01/25. https://doi.org/10.1056/NEJMoa011795 PMID: 11807147.

6. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large-B-cell lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24(19):3121–7. Epub 2006/06/07. https://doi.org/10.1200/JCO.2005.05.1003 PMID: 16754935.

7. Pfundenschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). The Lancet Oncology. 2008; 9(2):105–16. Epub 2008/01/30. https://doi.org/10.1016/S1470-2045(08)70002-0 PMID: 18226581.

8. Pfundenschuh M, Trumper L, Osterborg A, Pettengell R, Tmeny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet Oncology. 2006; 7(5):379–91. Epub 2006/05/02. https://doi.org/10.1016/S1470-2045(06)70664-7 PMID: 16648042.

9. Li Q, Li W, Wang L, Wang W, Niu S, Bi X, et al. Consolidation Radiotherapy in Stage IE- IIE, Non-Bulky Primary Gastric Diffuse Large B-Cell Lymphoma with Post-Chemotherapy Complete Remission. PLoS One. 2015; 10(7):e0133469. Epub 2015/07/21. https://doi.org/10.1371/journal.pone.0133469 PMID: 26193661; PubMed Central PMCID: PMC4508098.

10. Koch P, Probst A, Berdel WE, Willich NA, Reintz G, Brockmann J, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(28):7050–9. Epub 2005/08/01. https://doi.org/10.1200/JCO.2005.04.0316 PMID: 16129843.

11. Zhang J, Li G, Yang H, Liu X, Cao J. Rituximab in treatment of primary gastric diffuse large B-cell lymphoma. Leuk Lymphoma. 2012; 53(11):2175–81. Epub 2012/04/03. https://doi.org/10.3109/10428194.2012.680451 PMID: 22462613.
Role of local treatment in PG-DLBCL

12. d’Amore F, Christensen BE, Brincker H, Pedersen NT, Thorling K, Hastrup J, et al. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. European journal of cancer (Oxford, England: 1990). 1991; 27(10):1201–8. Epub 1991/01/01. https://doi.org/10.1016/0959-8049(91)90081-n PMID: 1835586.

13. Rohatiner A, d’Amore F, Collier B, Crowther D, Gospodarowicz M, Isaacson P, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphomas. Annals of oncology: official journal of the European Society for Medical Oncology. 1994; 5(5):397–400. Epub 1994/05/01. https://doi.org/10.1093/oxfordjournals.annonc.a058869 PMID: 8075046.

14. Barrington SF, Mikhaeel NG, Kostakoglou L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32(27):3048–58. Epub 2014/08/13. https://doi.org/10.1200/jco.2013.53.5229 PMID: 25117771; PubMed Central PMCID: PMC3015423 are found at the end of this article.

15. Liu X, Fang H, Tian Y, Wang WH, Song YW, Wang SL, et al. Intensity Modulated Radiation Therapy for Early-Stage Primary Gastric Diffuse Large B-Cell Lymphoma: Dosimetric Analysis, Clinical Outcome, and Quality of Life. Int J Radiat Oncol Biol Phys. 2016; 95(2):712–20. Epub 2016/04/02. https://doi.org/10.1016/j.ijrobp.2016.01.027 PMID: 27034178.

16. Ferreri AJ, Cordio S, Paro S, Ponzoni M, Freschi M, Veglia F, et al. Therapeutic management of stage I-II high-grade primary gastric lymphomas. Oncology. 1999; 56(4):274–82. Epub 1999/05/27. https://doi.org/10.1016/0000-0978(99)90019-3 PMID: 10343190.

17. Cortelazzo S, Rossi A, Roggero F, Oldani E, Zucca E, Tondini C, et al. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG). Annals of oncology: official journal of the European Society for Medical Oncology. 1999; 10(12):1433–40. Epub 2000/01/22. https://doi.org/10.1023/a:1008351427601 PMID: 10643533.

18. Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH, et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol. 2012; 91(9):1383–91. Epub 2012/04/25. https://doi.org/10.1007/s00277-012-1463-9 PMID: 22526364.

19. Liu YZ, Xue K, Wang BS, Li CY, Lv FF, Jin J, et al. The size and depth of lesions measured by endoscopic ultrasonography are novel prognostic factors of primary gastric diffuse large B-cell lymphoma. Leuk Lymphoma. 2019; 60(4):934–9. Epub 2018/10/03. https://doi.org/10.1080/10428194.2018.1515942 PMID: 30277105.

20. Ishikawa E, Tanaka T, Shimada K, Kohno K, Satou A, Eladl AE, et al. A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B-cell lymphoma in the rituximab era. Cancer Med. 2018. Epub 2018/06/02. https://doi.org/10.1002/cam4.1595 PMID: 29856127; PubMed Central PMCID: PMC4394239.

21. Jegadeesh N, Rajpara R, Esiashvili N, Shi Z, Liu Y, Okwan-Duodu D, et al. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation. Int J Radiat Oncol Biol Phys. 2015; 92(1):107–12. Epub 2015/01/09. https://doi.org/10.1016/j.ijrobp.2015.01.025 PMID: 25863758; PubMed Central PMCID: PMC4334239.

22. Tomita N, Takasaki H, Miyashita K, Fujisawa S, Ogusa E, Matsuura S, et al. R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma. Br J Haematol. 2013; 161(3):383–8. Epub 2013/02/26. https://doi.org/10.1111/bjh.12281 PMID: 23432318.

23. Hornig SJ, Weller E, Kim K, Earle JD, O’Connell MJ, Habermann TM, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004; 22(15):3032–8. Epub 2004/06/24. https://doi.org/10.1200/JCO.2004.06.088 PMID: 15210738.

24. Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, et al. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys. 2013; 86 (3):569–77. Epub 2013/04/02. https://doi.org/10.1016/j.ijrobp.2013.02.007 PMID: 23540349.

25. Fischbach W, Schramm S, Goebeler E. Outcome and quality of life favour a conservative treatment of patients with primary gastric lymphoma. Zeitschrift fur Gastroenterologie. 2011; 49(4):430–5. Epub 2011/04/09. https://doi.org/10.1023/a:10000129356.81281.0c PMID: 15213615; PubMed Central PMCID: PMC1356371.